We are live on ! Find out more
BB Biotech

BB Biotech Portfolio holdings

AUM $3.98B Turnover 8.33%
1-Year Est. Return 15.47%
This Fund
S&P 500
This Quarter Est. Return
-16.52%
1 Year Est. Return
+15.47%
3 Year Est. Return
+121.5%
5 Year Est. Return
+265.65%
10 Year Est. Return
–
AUM
$3.12B
AUM Growth
-$658M
Cap. Flow
+$105M
Cap. Flow %
3.38%
Top 10 Hldgs %
64.02%
Holding
36
New
4
Increased
20
Reduced
3
Closed
2
Avg Time Held
2.9 years
Top 10 Avg Time Held
2.8 years
Top 20 Avg Time Held
3.3 years

Top Buys

Rank Stock Value
1
MRNA icon
Moderna
MRNA
+$78.6M
2
AGIO icon
Agios Pharmaceuticals
AGIO
+$42M
3
SAGE icon
Sage Therapeutics
SAGE
+$34.8M
4
SRRK icon
Scholar Rock
SRRK
+$24.7M
5
NKTR icon
Nektar Therapeutics
NKTR
+$21.6M

Top Sells

Rank Stock Value
1
TSRO
TESARO, Inc.
TSRO
+$114M
2
CELG
Celgene Corp
CELG
+$50.2M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$48.3M
4
GILD icon
Gilead Sciences
GILD
+$43.5M
5
ACHN
Achillion Pharmaceuticals
ACHN
+$4.71M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
IONS icon
1
Ionis Pharmaceuticals
IONS
$4.6B
$473M 15.14%
8,741,334
+75,000
+0.9% +$3.83M
2013 Q2
22 quarters
INCY icon
2
Incyte
INCY
$24.7B
$242M 7.76%
3,808,322
– –
2013 Q2
22 quarters
NBIX icon
3
Neurocrine Biosciences
NBIX
$17.1B
$239M 7.65%
3,343,090
+185,000
+6% +$17.7M
2013 Q3
21 quarters
VRTX icon
4
Vertex Pharmaceuticals
VRTX
$138B
$227M 7.28%
1,370,445
– –
2013 Q2
22 quarters
ESPR icon
5
DELISTED
Esperion Therapeutics
ESPR
$156M 5%
3,392,964
+110,000
+3% +$5.3M
2015 Q3
13 quarters
CELG
6
DELISTED
Celgene Corp
CELG
$148M 4.73%
2,303,875
-680,423
-23% -$50.2M
2013 Q2
22 quarters
AGIO icon
7
Agios Pharmaceuticals
AGIO
$1.86B
$133M 4.25%
2,878,134
+680,203
+31% +$42M
2014 Q2
18 quarters
SAGE icon
8
DELISTED
Sage Therapeutics
SAGE
$132M 4.22%
1,375,229
+303,856
+28% +$34.8M
2015 Q4
12 quarters
ALXN
9
DELISTED
Alexion Pharmaceuticals
ALXN
$128M 4.1%
1,314,428
– –
2013 Q2
22 quarters
HALO icon
10
Halozyme
HALO
$11.4B
$122M 3.9%
8,322,860
+75,000
+0.9% +$1.2M
2013 Q2
22 quarters
ALNY icon
11
Alnylam Pharmaceuticals
ALNY
$21.5B
$115M 3.67%
1,571,389
+200,851
+15% +$15.4M
2013 Q2
22 quarters
RDUS icon
12
DELISTED
Radius Health, Inc.
RDUS
$111M 3.54%
6,710,276
+120,000
+2% +$2.02M
2014 Q2
18 quarters
ARGX icon
13
argenx
ARGX
$61B
$85M 2.72%
884,739
+150,000
+20% +$13.3M
2018 Q1
3 quarters
GILD icon
14
Gilead Sciences
GILD
$209B
$83.3M 2.67%
1,332,204
-622,392
-32% -$43.5M
2013 Q2
22 quarters
MRNA icon
15
Moderna
MRNA
$90.6B
$73.1M 2.34%
+4,785,681
New +$78.6M
2018 Q4
0 quarters
AKCA
16
DELISTED
Akcea Therapeutics Inc
AKCA
$71.9M 2.3%
2,386,471
– –
2017 Q4
4 quarters
WVE icon
17
Wave Life Sciences
WVE
$607M
$61.6M 1.97%
1,465,002
+80,000
+6% +$3.56M
2017 Q4
4 quarters
MYOV
18
DELISTED
Myovant Sciences Ltd.
MYOV
$59M 1.89%
3,597,882
+30,000
+0.8% +$591K
2016 Q4
8 quarters
ICPT
19
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$58M 1.86%
575,719
+30,000
+5% +$3.11M
2015 Q1
15 quarters
EXEL icon
20
Exelixis
EXEL
$17B
$55.8M 1.79%
2,835,000
+50,000
+2% +$891K
2018 Q2
2 quarters
NKTR icon
21
Nektar Therapeutics
NKTR
$1.26B
$45.4M 1.45%
92,065
+35,732
+63% +$21.6M
2018 Q2
2 quarters
MYOK
22
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$42.9M 1.37%
877,266
+367,266
+72% +$20.2M
2018 Q2
2 quarters
MGNX icon
23
MacroGenics
MGNX
$143M
$41.7M 1.34%
3,283,272
+292,860
+10% +$4.91M
2016 Q2
10 quarters
SRRK icon
24
Scholar Rock
SRRK
$5.24B
$29.4M 0.94%
1,279,978
+1,090,021
+574% +$24.7M
2018 Q3
1 quarter
ALDR
25
DELISTED
Alder Biopharmaceuticals
ALDR
$28.4M 0.91%
2,766,008
+500,000
+22% +$6.4M
2015 Q2
14 quarters
1
2

Similar funds

Santa Barbara Asset Management
Santa Barbara Asset Management Los Angeles, California $6.43B AUM 10.99% 1-Year Est. Return
HL Financial Services
HL Financial Services Louisville, Kentucky $6.5B AUM 9.56% 1-Year Est. Return
SA
SQ Advisors Naples, Florida $1.32B AUM 10.3% 1-Year Est. Return
WealthTrust Fairport
WealthTrust Fairport Cleveland, Ohio $1.06B AUM 3.47% 1-Year Est. Return
Bain Capital Public Equity Management
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
Daruma Capital Management
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
AT Bancorp
AT Bancorp Dubuque, Iowa $823M AUM 0.35% 1-Year Est. Return
MB Financial Bank - Trust Department
MB Financial Bank - Trust Department Rosemont, Illinois $816M AUM 5.49% 1-Year Est. Return

BB Biotech's Q4 2018 Portfolio in Review

As of Q4 2018, BB Biotech held 36 positions worth $3.12B, down 17% from $3.78B the previous quarter. Its ten largest holdings account for 64% of the portfolio.

BB Biotech deployed $105M of net new capital in Q4 2018, opening 4 new positions and adding to 20 existing holdings. Its largest new stake was Moderna: 4,785,681 shares worth $73.1M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Celgene Corp, an estimated $50.2M trimmed.

  • BB Biotech's largest Q4 2018 buy was Moderna: 4,785,681 shares worth $73.1M.
  • BB Biotech added most to Agios Pharmaceuticals in Q4 2018, an estimated $42M increase.
  • BB Biotech's biggest Q4 2018 reduction was Celgene Corp, cutting an estimated $50.2M.
  • BB Biotech fully exited TESARO, Inc. in Q4 2018, selling an estimated $114M.
  • BB Biotech's ten largest holdings make up 64% of its $3.12B portfolio in Q4 2018.
  • BB Biotech opened 4 new positions and closed 2 in Q4 2018.
  • BB Biotech's portfolio value fell 17% quarter-over-quarter to $3.12B.

Based on BB Biotech's 13F filing for Q4 2018, filed 12 Feb 2019.